Vimarsana
Biggest News Aggregation in the World

Page 2 - Alligator Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alligator Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alligator Bioscience Today - Breaking & Trending Today

Strong team behind the new SmiLe company Uptake Bio - Vimarsana News

Strong team behind the new SmiLe company Uptake Bio

 SmiLe IncubatorView in browser Strong team behind the new SmiLe company Uptake BioPress release2023-06-28 11:05Anki Malmborg Hager, CEO of Uptake Bio Lund Sweden – Uptake Bio is developing revolutionary radioimmunotherapy drugs that have the ability to target radiotherapy to specific cancer cel...

First-line Mitazalimab Plus Chemo Continues to Generate Responses in Metastatic PDAC - Vimarsana News

First-line Mitazalimab Plus Chemo Continues to Generate Responses in Metastatic PDAC

Frontline treatment with the combination of the CD40-directed monoclonal antibody agonist mitazalimab and modified FOLFIRINOX continued to produce responses in patients with metastatic pancreatic ductal adenocarcinoma.

FDA Grants Orphan Drug Designation to Mitazalimab in Pancreatic Cancer - Vimarsana News

FDA Grants Orphan Drug Designation to Mitazalimab in Pancreatic Cancer

The FDA has granted an orphan drug designation to mitazalimab for use as a potential therapeutic option in patients with pancreatic cancer.

BioStock Investor Pitch: Alligator Bioscience - Vimarsana News

BioStock Investor Pitch: Alligator Bioscience

Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for... | May 4, 2023

Amphera and Alligator Bioscience reveal mitazalimab-MesoPher update - Vimarsana News

Amphera and Alligator Bioscience reveal mitazalimab-MesoPher update

Therapy is being used during pivotal phase 1 study into patients with pancreatic cancer - News - PharmaTimes